EUVIMEDEUVIMED entdecken
Crossref

Thulium: yttrium-aluminiumgarnet laser transurethral vapoenucleation – a new standard in the surgical treatment of large benign prostatic hyperplasia

Alexei Plesacov, Ivan Vladanov, Vitalii Ghicavii

Moldovan Journal of Health Sciences · 2022

DOI: 10.52645/mjhs.2022.2.02 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Moldovan Journal of Health Sciences, 2022. Verfasst von Alexei Plesacov und 2 weiteren Autor:innen. Die Arbeit nennt 18 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

According to the current recommendations of the European Association of Urology and the International Society of Urology, open simple prostatectomy is the reference standard in the surgical treatment of benign prostatic hyperplasia of large size (>80 ml). Extended trauma and a high complication rate reduce the chances to use this method. In this context, several minimally invasive laser surgical treatment techniques have been proposed in order to provide an optimal treatment to patients. Transurethral endoscopic vapoenucleation of the prostate using laser energy is a new concept in endourological surgery. Material and methods. Between September 2019 and December 2019, 93 patients with benign prostatic hyperplasia underwent surgical treatment. Two surgical methods were applied: transurethral Thulium:YAG laser prostate vapoenucleation (45 patients) and open simple prostatectomy (48 patients). All patients were evaluated preoperatively and postoperatively (3 and 6 months) using the International Prostate Symptom Score, Quality of Life Score and International Erectile Function Index, physical examination and digital rectal examination, prostate specific antigen assessment, transrectal prostate ultrasound examination and assessment of residual urine volume, uroflowmetry. Postoperative complications were recorded according to the Clavien-Dindo classification, 2004. The inclusion criteria were total prostate volume ≥80 cm3, age ≤80 years, residual urine volume ≥70 ml, Qmax ≤10 ml/s.

Results

Transurethral Thulium:YAG laser vaponucleation of prostate has proven a high surgical efficiency level. The baseline urodynamic and ultrasonographic indicators after transurethral vapoenucleation at 6 months postoperatively were similar to those in the control group (open simple prostatectomy). The duration of recovery of patients after classical surgery was significantly longer. At the same time, the rate of postoperative complications after prostate vapoenucleation was lower. Patients in the ThuVEP group did not require blood transfusions.

Conclusions

According to obtained results, we can assume that transurethral vapoenucleation of the prostate with laser energy will soon become a new „gold standard” in the surgical treatment of large benign prostate hyperplasia.

Zitieren

APA

Plesacov, A., Vladanov, I., & Ghicavii, V. (2022). Thulium: yttrium-aluminiumgarnet laser transurethral vapoenucleation – a new standard in the surgical treatment of large benign prostatic hyperplasia. Moldovan Journal of Health Sciences. https://doi.org/10.52645/mjhs.2022.2.02

Vancouver

Plesacov A, Vladanov I, Ghicavii V. Thulium: yttrium-aluminiumgarnet laser transurethral vapoenucleation – a new standard in the surgical treatment of large benign prostatic hyperplasia. Moldovan Journal of Health Sciences. 2022. doi:10.52645/mjhs.2022.2.02

BibTeX
@article{Plesacov2022,
  author = {Plesacov, Alexei and Vladanov, Ivan and Ghicavii, Vitalii},
  title = {Thulium: yttrium-aluminiumgarnet laser transurethral vapoenucleation – a new standard in the surgical treatment of large benign prostatic hyperplasia},
  journal = {Moldovan Journal of Health Sciences},
  year = {2022},
  doi = {10.52645/mjhs.2022.2.02}
}
Kostenlos starten →